Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 3Recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Oropharyngeal Neoplasms 1

Interventions

pembrolizumab 562Specimen Handling 490Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 406Radiotherapy 353Gemcitabine 314Bevacizumab 313Paclitaxel 298Biopsy 290Drug Therapy 283Blood Specimen Collection 248Capecitabine 245Oxaliplatin 241fludarabine 240Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 205Dexamethasone 187Radiosurgery 182Rituximab 159Standard of Care 158Pemetrexed 156Surgical Procedures, Operative 148durvalumab 145atezolizumab 145Leucovorin 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Vaccines, DNA × Clear all
NCT06631092 2026-05-26

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

NEC Bio B.V

Phase 1/2 Recruiting
28 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05799144 2025-10-22

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
54 enrolled
Head & Neck

Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡